Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HOSTRESPONSE

Financiado

Cerrado

Host molecular and cellular responses to anti cancer drug treatment as a potenti...

Host molecular and cellular responses to anti cancer drug treatment as a potential biomarker for treatment outcome Chemotherapy remains one of the most common treatment modalities for cancer. It is typically administered in cycles of bolus injections following 21 days of drug-free break periods. However, tumor regrowth between drug intervals i... ver más

28/02/2017

TECHNION ISRAEL I...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-02-28 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TECHNION ISRAEL INSTITUTE O...

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BMDCS IN CANCER The impact of bone marrow derived cells on tumor growth and... 100K€ Cerrado

SAF2010-15661 SEÑALIZACION POR PI3K EN ANGIOGENESIS; UNA NUEVA DIANA TERAP... 145K€ Cerrado

STROMALIGN Mechanisms and Targeting Stromal Contribution to Tumour Inva... 1M€ Cerrado

AngioResist Coordinated Development of Inhibitors and Biomarkers for Res... 150K€ Cerrado

CARE1 First line randomized study platform to optimize treatment i... 6M€ Cerrado

SAF2015-70820-ERC PREDICCION DE LA RESPUESTA A LOS FARMACOS ANTIANGIOGENICOS:... 60K€ Cerrado

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Chemotherapy remains one of the most common treatment modalities for cancer. It is typically administered in cycles of bolus injections following 21 days of drug-free break periods. However, tumor regrowth between drug intervals is often observed, due in part, to rebound angiogenesis. Our previous studies demonstrated that bone marrow derived proangiogenic cells are acutely mobilized following certain chemotherapy treatments, accompanied by enhanced tumor angiogenesis, which can be blocked by prior treatment with antiangiogenic drugs. These findings indicate that unknown host-derived mechanisms induced by chemotherapy, can stimulate tumor growth. Since the efficacy of antiangiogenic drugs is dependent on several parameters such as tumor type, stage, and the type of chemotherapy, such a therapy is not beneficial for all patients, and thus, necessitates the identification of surrogate biomarkers to predict clinical outcome. To address this issue, we will integrate basic, translational, and clinical approaches to: (i) identify molecular and cellular host systemic responses following treatments; (ii) isolate novel factors by proteomic approaches which are altered during the course of the treatment, and evaluate their feasibility as biomarkers to predict clinical outcome; (iii) determine the relevance of these factors in clinical specimens; (iv) screen for therapeutic compounds which can block host responses mediating tumor growth in order to increase treatment efficacy. We believe that this strategy of combined approach will lead to the development of new tools in clinical oncology. Profiling individual host response to anti-cancer drug treatment may serve as a biomarker for treatment outcome and further promote the concept of personalised medicine in cancer therapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores